Equities Analysts Offer Predictions for Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR) – Analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Cencora in a report released on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.23 per share for the quarter, up from their prior forecast of $4.12. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

Other analysts have also issued research reports about the company. Evercore ISI upped their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Finally, Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Cencora Stock Up 2.0 %

Cencora stock opened at $229.20 on Monday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market capitalization of $44.30 billion, a price-to-earnings ratio of 30.52, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. Cencora has a fifty-two week low of $207.63 and a fifty-two week high of $253.27. The stock’s fifty day moving average is $237.44 and its two-hundred day moving average is $233.60.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.96%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,696 shares of company stock valued at $22,862,734. Insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

A number of large investors have recently modified their holdings of the company. Lake Street Advisors Group LLC raised its holdings in shares of Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after purchasing an additional 43 shares during the period. Venturi Wealth Management LLC raised its holdings in shares of Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after buying an additional 46 shares during the period. Prime Capital Investment Advisors LLC raised its holdings in shares of Cencora by 1.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after buying an additional 46 shares during the period. J.W. Cole Advisors Inc. raised its holdings in shares of Cencora by 1.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after buying an additional 48 shares during the period. Finally, Impact Partnership Wealth LLC raised its holdings in shares of Cencora by 2.6% during the 3rd quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock valued at $460,000 after buying an additional 51 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.